Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Multicentre, Open-label, Dose Escalation and Randomized Trial of BI 836858 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes

NCT02240706 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT02240706
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02240706 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Multicentre, Open-label, Dose Escalation and Randomized Trial of BI 836858 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes
Lead sponsor
Boehringer Ingelheim
Phase
Phase 2
Overall status
Terminated
Start date
January 22, 2015
Completion date
November 18, 2019
Enrollment
27 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndromes